Articles > Popular publications > PR Newswire press releases > April-June 2008 > Thursday, May 8

Article: Micromet, Inc. Reports First Quarter 2008 Financial Results.

Article from:
PR Newswire
Article date:
May 8, 2008
Copyright

BETHESDA, Md., May 8 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company focusing on the development of novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced its financial results for the first quarter ended March 31, 2008. 

 
  Summary of Recent Events: 
 
  -- In April, Micromet announced the initiation of the first phase 1 
 clinical trial with its BiTE(R) antibody MT110. The study will explore 
 the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity 
 of MT110 in patients with lung cancer and patients with 
 gastrointestinal cancer. MT110 targets the ...

Read all of this article with a FREE trial

Related newspaper, magazine, and journal articles:

Article: Micromet Enters Into Agreement for Solid Tumor BiTE ...
PR Newswire;  January 12, 2009 ;     700+ words ... ... secure a one year option on a specific BiTE antibody. Bayer Schering Pharma may exercise ... Schering Pharma on the development of the BiTE antibody through the completion of phase 1 clinical ... development and commercialization of the BiTE antibody. Micromet would be eligible for an ...

Article: Micromet Announces Presentation of Five Posters Related to Its ...
PR Newswire;  March 18, 2008 ;     700+ words ... ... therapy. A first poster reports that BiTE antibody MT110, which has completed preclinical ... a second poster is presented where BiTE antibody MT103 (MEDI-538), which is in ... therapeutic index of an anti-EpCAM BiTE antibody in a mouse model (abstract no. 2130 ...

Article: Preclinical Study Published in Cancer Research Demonstrates ...
PR Newswire;  January 22, 2008 ;     700+ words ... ... the safety profile of an EpCAM-specific BiTE antibody, Micromet's researcher constructed a murine- specific BiTE antibody, called muS110, that is similar to the human-specific BiTE antibody MT110 with respect to structure, binding ...

Article: Micromet Presents Update on BiTE Antibody Pipeline ...
PR Newswire;  April 24, 2009 ;     700+ words ... ... of development across Micromet's BiTE antibody platform and included updates on: -- BiTE antibody Blinatumomab -- a rapid path to market ... Hematology meeting in December. -- BiTE antibody MT110 -- data presented at this week ...

Article: New Data Published in Immunobiology Describe Mode of Action of ...
PR Newswire;  January 28, 2009 ;     700+ words ... ... amounts of Micromet's EpCAM-targeting BiTE antibody trigger the death of cancer cells BETHESDA ... describing in detail the mode of action of BiTE antibody MT110. MT110 is a T cell-engaging ... cell lysis, which is necessary for BiTE antibody-activated T cells to adopt a serial ...

Article: Micromet's BiTE Antibody Blinatumomab ...
PR Newswire;  June 5, 2008 ;     700+ words ... ... data(1) with the CD19-specific BiTE antibody show that all seven patients in the ... member and a member of Micromet's BiTE Antibody Scientific Advisory Board. "The data ... R. et al. (2008). Anti-CD19 BiTE Antibody MT103 (MEDI-538) Induces Durable ...

Article: Micromet Receives European Orphan Drug Designation for Treatment ...
PR Newswire;  August 3, 2009 ;     700+ words ... ... European Medicines Agency (EMEA) for BiTE antibody blinatumomab (MT103) for acute lymphoblastic ... antibodies generated with its proprietary BiTE antibody platform, as well as conventional ... currently in clinical trials. Its BiTE antibody blinatumomab (MT103) is in a phase ...

Article: Micromet Enrolls First Patient in a Phase 1 Clinical Trial with ...
PR Newswire;  April 23, 2008 ;     700+ words ... ... these cancers. MT110 is the second BiTE antibody in clinical trials, and the fourth ... Micromet's product pipeline. The first BiTE antibody, MT103 (MEDI-538), is now in ... obtained clinical proof of concept for our BiTE antibody technology with MT103 in haematological ...

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!

Find articles, research, and archives